Prognosis

Neuvivo Expands Management Team Adding Gregg Fergus, Former President of Ion Torrent, as Head of Strategy and Business Development and to the Board of Directors

Retrieved on: 
Wednesday, January 5, 2022
LM, Time, PALO, Ion semiconductor sequencing, Doctor of Philosophy, RW, Head, Patient, Affymetrix, DNA, Life, Butterfly network, Life Technologies, Prognosis, University of Wisconsin–Madison, Neurodegeneration, CEO, Business development, Senior, Wisconsin Institutes for Discovery, Board, AIQ, ALS, Board of directors, Drug development, COO, QSI, Cellular Dynamics International, Management, Pharmaceutical industry, Bacteriology

"We are delighted to have Gregg join Neuvivo at this stage as we accelerate both our drug development and capital-raising activities," said Ari Azhir, PhD, Neuvivo founder and CEO.

Key Points: 
  • "We are delighted to have Gregg join Neuvivo at this stage as we accelerate both our drug development and capital-raising activities," said Ari Azhir, PhD, Neuvivo founder and CEO.
  • "Gregg brings strong commercial, operational skills and an impressive record of value creation as well as a clear passion to help improve the treatment options for ALS patients."
  • "I am truly excited to be joining the distinguished team at Neuvivo and passionate about bringing life changing treatments to ALS patients and families," said Gregg Fergus.
  • "Neuvivo has recorded significant achievements with respect to understanding ALS and developing a novel drug candidate the time is right now to move NP001 toward commercialization."

Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference

Retrieved on: 
Wednesday, January 5, 2022
Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Conference, Prognosis, LSE, EST, Kidney disease, Risk assessment, NASDAQ, CKD, SALT, GLOBE, Interest, Pharmaceutical industry

NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.

Key Points: 
  • NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.
  • Renalytixs management is scheduled to present on Wednesday, January 12, 2022, at 2:15 p.m. EST.
  • Interested parties may access a live and archived webcast of the presentation on the Investors section of the company website at investors.renalytix.com .
  • Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis for kidney health.

Amyloidosis News to Present Disease State Education on ATTR-CM

Retrieved on: 
Wednesday, January 5, 2022
Lynx, Academy, Caregiver, TLG, Program, Association, News, Nursing, Research, Pharmacist, Patient, Physician, Report, TTR, Oncology, Quality of life, Prognosis, Amyloidosis, Diagnosis, Cardiac amyloidosis, Heart failure, Medical device, Pharmaceutical industry, Medicine, ATTR

This master class series, consisting of 5 half-hour virtual programs, is designed to provide disease state education on ATTR-CM, which is a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that is associated with heart failure.

Key Points: 
  • This master class series, consisting of 5 half-hour virtual programs, is designed to provide disease state education on ATTR-CM, which is a rare, life-threatening, underrecognized, and underdiagnosed type of amyloidosis that is associated with heart failure.
  • The third program, titled "Tools to Diagnose and Monitor ATTR-CM," will be held at 12 p.m. on January 18, 2022.
  • Amyloidosis News is an educational resource for healthcare providers who treat patients with heart failure to promote early diagnosis and improved treatment outcomes in patients with cardiac amyloidosis.
  • The Lynx Group (TLG) is a premier medical communications and education company acutely focused on oncology and rare disease states.

American Diabetes Association and Renalytix Partner to Prioritize Kidney Health in Type 2 Diabetes Population

Retrieved on: 
Tuesday, January 4, 2022
ADA, Chronic kidney disease, KPI-driven code analysis, Centers for Disease Control and Prevention, Dialysis, Disease, Biomarker, Risk, Gaps, Prediabetes, CDC, Canadian Foundation for Healthcare Improvement, Diabetes, Bank account, Health, GLOBE, Quality of life, Kidney disease, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Life, Food, Physician, SALT, Prognosis, Health care, DKD, American Diabetes Association, CEO, T2D, LSE, Research, Heart, CKD, Adult, Program, Patient, Type 2 diabetes, Education, Technology, Breast, Public health, Center, Pharmaceutical industry, Facebook, Instagram

Early identification and risk-informed care are critical to better health outcomes, said Dr. Nuha El Sayed, Vice President of Healthcare Improvement at the American Diabetes Association.

Key Points: 
  • Early identification and risk-informed care are critical to better health outcomes, said Dr. Nuha El Sayed, Vice President of Healthcare Improvement at the American Diabetes Association.
  • Together, ADA and Renalytix will convene experts to advise and develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction.
  • Join the fight with us on Facebook ( American Diabetes Association ), Spanish Facebook ( Asociacin Americana de la Diabetes ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn ).
  • Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisfor kidney health.

Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering

Retrieved on: 
Monday, January 3, 2022
Safety, Securities Exchange Act of 1934, Rights, Lung cancer, Diagnosis, Investor, Pharma, COVID-19, Private Securities Litigation Reform Act, Franciscan Ceramics, Risk, U.S. Securities and Exchange Commission, CEP, Prospectus, Cancer, Sumathi Best Television Current Reporting Award, Goal, GLOBE, Ownership, Company, Physician, Prognosis, Pancreatic cancer, SEC, Terminology, Health, Form, Exercise, Securities Act of 1933, Thyroid cancer, Esophageal cancer, Drug development, Security (finance), Technology, Time, Sale, Pancreatic cyst, Industry

PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it has set the record date for its proposed fully back-stopped $30 Million Rights Offering.

Key Points: 
  • PARSIPPANY, NJ, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG) today announced that it has set the record date for its proposed fully back-stopped $30 Million Rights Offering.
  • Holders who fully exercise their rights may subscribe for additional shares not subscribed for by other holders on a pro rata basis.
  • The subscription price per whole share of common stock in the Rights Offering has not yet been determined.
  • The proposed Rights Offering will be made pursuant to such registration statement, as it may be amended from time to time, and a final prospectus to be filed with the SEC prior to the commencement of the proposed rights offering.

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

Retrieved on: 
Monday, January 3, 2022
COVID-19, Risk, U.S. Securities and Exchange Commission, Interneuron, Mortality, Drug resistance, CEO, Epilepsy, Prognosis, Magloire, Lennox–Gastaut syndrome, Seizure, NEW, Dravet syndrome, Company, Research, SEC, Program, Harvard Medical School, KCC2, Biopharmaceutical, CNS, AstraZeneca, RNA, Genetics, GLOBE, Neuron, Lists of diseases, Angelman syndrome, Spasm, Allen J. Ellender, Potassium chloride, S, Security (finance), Tuberous sclerosis, Technology, A, Brain, Neuropharmacology, NASDAQ, DRS, MB, Patient, Acquisition, P, Neurodegeneration, Forward-looking statement, Acceleration, Pharmaceutical industry, Neuroscience, Takeda

The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.

Key Points: 
  • The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.
  • The KCC2 transporter is an exciting and novel target that we believe holds great promise in treating epilepsies, said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid.
  • Ovids focus in neuroscience and experience in developing novel anti-epileptics make it an optimal choice to advance KCC2 activators, including OV350, noted Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals R&D, AstraZeneca.
  • OV350 is an early-stage compound that has shown encouraging in-vitro and in-vivo proof of concept in resistant forms of epilepsy.

Mission Bio and SequMed Sign Collaboration Agreement Announcing Partnership to Provide Tapestri Services and Co-Develop Clinical Applications in China

Retrieved on: 
Thursday, December 30, 2021
Growth, Data analysis, Diagnosis, DNA, Cancer, Neoplasm, Medicine, Health, Solution, B cell, Partnership, Prognosis, CEO, Mayfield (company), Hospital, Telecommunication Technology Committee, Therapy, Drug development, Reproductive health, Adoption, Agilent Technologies, DNA methylation, BD, Chromatin, Acceleration, Fine chemical, Tapestry (disambiguation)

The agreement will allow Mission Bio to expand its product and services offerings into China, a key region of growth for its geographical expansion strategy, enabling high quality single-cell sequence services using Mission Bio's products to customers in mainland China.

Key Points: 
  • The agreement will allow Mission Bio to expand its product and services offerings into China, a key region of growth for its geographical expansion strategy, enabling high quality single-cell sequence services using Mission Bio's products to customers in mainland China.
  • This partnership builds on Mission Bio's commitment to providing high quality single-cell multi-omics with the Tapestri platform in China, where there is an increasing demand for single-cell innovation for clinical diagnosis.
  • "Tumor heterogeneity is always one of the biggest challenges for cancer therapy and the development of treatment resistance," said Yan Zhang, CEO of Mission Bio.
  • We look forward to working with Mission Bio to develop novel single-cell assays for different diseases, from molecular mechanism elucidation to clinical medicine acceleration.

Siemens Healthineers Announces FDA Emergency Use Authorization For CLINITEST® Rapid COVID-19 Antigen Self-Test

Retrieved on: 
Wednesday, December 29, 2021
Medical Devices, Medical Supplies, Infectious Diseases, FDA, Biotechnology, Health, Pharmaceutical, Other Science, Science, Power-on self-test, Safety, Unitary state, National, Diagnosis, COVID-19, EBIT, US, CDC, Protein, BBC, FDA, PCR, Doctor of Philosophy, ITAP, Siemens Healthineers, COVID-19 testing, EUA, Severe acute respiratory syndrome coronavirus 2, Government, Solution, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Partnership, Prognosis, Multimedia, Korea Disease Control and Prevention Agency, Inflammation, OTC, Federal Food, Drug, and Cosmetic Act, Emergency Use Authorization, Virus, Acceleration, Point, Patient, Infection, Hematology, Coagulation, Center, Pharmaceutical industry, Vaccine, Medical imaging

Siemens Healthineers announces that the U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for the CLINITEST Rapid COVID-19 Antigen Self-Test,1, 2, 3 providing nationwide access to a new at-home or over-the-counter self-test as COVID-19 testing needs continue to grow for individuals, families, and businesses.

Key Points: 
  • Siemens Healthineers announces that the U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for the CLINITEST Rapid COVID-19 Antigen Self-Test,1, 2, 3 providing nationwide access to a new at-home or over-the-counter self-test as COVID-19 testing needs continue to grow for individuals, families, and businesses.
  • View the full release here: https://www.businesswire.com/news/home/20211229005379/en/
    Siemens Healthineers announces FDA Emergency Use Authorization for CLINITEST Rapid COVID-19 Antigen Self-Test for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).
  • With the CLINITEST Rapid COVID-19 Antigen Self-Test, consumers will have access to a fast, reliable, and convenient test to provide additional safety, said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers.
  • 3 In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization.

Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma

Retrieved on: 
Tuesday, December 28, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Thought, EZH2, ADC, Quality of life, Daiichi Sankyo, Patient, Peripheral T-cell lymphoma, Paced Auditory Serial Addition Test, DXD, ORR, Cancer, ODD, Incidence, Survival, ATL, Program, Progression-free survival, Research, Alpha, Death, ASH, Adult, Ministry of Health, Labour and Welfare, Technology, Health care system in Japan, EZH1, Laboratory, Society, Cardiovascular disease, NHL, Safety, Orphan drug, Doctor of Philosophy, NDA, PTCL, MHLW, Central, Sustainable development, Prognosis, Pharmaceutical industry, Fine chemical, Health, Limited, Adult T-Cell Leukemia/Lymphoma, Valemetostat, the Pivotal Phase 2 Study, Daiichi Sankyo, ADULT T-CELL LEUKEMIA/LYMPHOMA, VALEMETOSTAT, THE PIVOTAL PHASE 2 STUDY, DAIICHI SANKYO

Valemetostat previously received Orphan Drug designation (ODD) from the Japan MHLW for treatment of patients with relapsed/refractory ATL.

Key Points: 
  • Valemetostat previously received Orphan Drug designation (ODD) from the Japan MHLW for treatment of patients with relapsed/refractory ATL.
  • Valemetostat is the fifth innovative oncology medicine from our pipeline to be submitted for regulatory approval in Japan in the past three years.
  • Valemetostat received ODD from the U.S. Food & Drug Administration for the treatment of PTCL in December 2021, ODD from the Japan MHLW for the treatment of relapsed/refractory ATL in November 2021 and SAKIGAKE Designation from the Japan MHLW for the treatment of adult patients with relapsed/refractory PTCL in April 2019.
  • A total of 25 patients were enrolled in the study in Japan.

United States Athletic Shoe Market Growth to 2027: Growing E-Commerce Retail Market Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
Fashion, Retail, PUMA, Distribution, Reebok, USD, Market share, Porter's five forces analysis, Others, Prognosis, Ecosystem, CAGR, Retail, ASICS

The United States Athletic Shoe Market was valued at USD 18,770.37 Million in 2019 and is projected to reach USD 24,533.84 Million by 2027, growing at a CAGR of 3.53 % from 2020 to 2027.

Key Points: 
  • The United States Athletic Shoe Market was valued at USD 18,770.37 Million in 2019 and is projected to reach USD 24,533.84 Million by 2027, growing at a CAGR of 3.53 % from 2020 to 2027.
  • The United States Athletic Shoe Market report provides a holistic evaluation of the market for the forecast period.
  • The report also focuses on the competitive landscape of the United States Athletic Shoe Market.
  • The United States Athletic Shoe Market is segmented on the basis of End-User, Product Type, and Distribution Channel.